Importantly, semaglutide does not suppress appetite through stimulant effects (like phentermine) or by altering serotonin pathways (like older weight loss drugs)
Separately, a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) by Godfrey et al., published in the Journal of the European Academy of Dermatology and Venereology (2025), found an elevated reporting odds ratio for alopecia with semaglutide of 2.46 (95% CI: 2.142.83)
Similar patterns are expected with retatrutide, as the underlying biological drivers of appetite are being managed by the medication, not permanently altered
About the Nitrous Oxide B12 Deficiency Lawsuit What Is Nitrous Oxide-Induced Vitamin B12 Deficiency
Consumers are increasingly seeking ingestible solutions for skin brightening, wrinkle reduction, and overall radiance
NICE Technology Appraisal 664